790.00 DA

FC:1801





PTO/SB/30 (04-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE a collection of information unless it displays a valid OMB control number

Officer the Paperwork Reduction Act of 1999, no persons are required to	Tooperia to a concentration intermatic	Transcott Diopicy of Talia and Call				
Request	Application Number	10/052,386-Conf. #5995				
For	Filing Date	January 18, 2002				
Continued Examination (RCE)						
Transmittal	First Named Inventor	Anil Saksena				
Address to: MS RCE	Art Unit	1653				
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Examiner Name	R. B. Mondesi				
AICALINIA, VV. 22010 1400	Attorney Docket Number	SCHERING 3.0-122 CIP				
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.						

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. 1. Submission required under 37 CFR 1.114 | Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _ i. Other ii **Enclosed** Х X Amendment/Reply Information Disclosure Statement (IDS) Copy of European Search Report Other Copies of cited references Affidavit(s)/Declaration(s) 2. Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. 3. Fees The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments to Deposit Account No. 12-1095 . I have enclosed a duplicate copy of this sheet. X RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) iii. Other Check in the amount of \$ enclosed b. Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED						
Signature	James Te	Date	May 19	, 2005		
Name (Print/Type)	Harvey L. Cohen	Registra	ation No.	28,365		

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Bas 1450, Alexandria, VA 22313-1450, on the date shown below

Dated: May 19, 2005

Signature:

(Harvey L. Cohen)

PE CIES

AMENDMENT TRANSMITTAL LETTER

Docket No. SCHERING 3.0-122

Application No. Filing Date Examiner Art Unit 10/052,386-Conf. #5995 January 18, 2002 R. B. Mondesi 1653

Applicant(s): Anil Saksena

Invention: NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

		CLAIM	S AS AMENI	DED		
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present		Rate	
Total Claims	78	- 128 =		х		
Independent Claims	6	- 15 =		x		
Multiple Depend	lent Claims (ch	eck if applicabl	e)			
Other fee (pleas	e specify):					
TOTAL ADDIT	IONAL FEE FO	OR THIS AME	NDMENT:			0.00
x Large Entity					Small Entity	,
x No additiona		d for this amer	ndment.		•	
Please charge Deposit Account No in the amount of \$ A duplicate copy of this sheet is enclosed.						
A check in the amount of \$ to cover the filing fee is enclosed.						
Payment by credit card. Form PTO-2038 is attached.						
The Director is hereby authorized to charge and credit Deposit Account No12-1095 as described below. A duplicate copy of this sheet is enclosed.						
	ny overpaymer					
x Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.						
Jano					Dated:	May 19, 2005
Harvey L. Cohe Attorney Reg. N						
LERNER, DAVI 600 South Aver Westfield, New (908) 518-6425	nue West Jersey 07090	RG, KRUMHO	LZ & MENTL	IK, LLI	Þ	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450, on the date shown

below.

Dated: May 19, 2005

Signatures

(Harvey L. Cohen)

PE CON TRADEMANT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria (A) 22313-450, on the date shown below.

ted: May 19, 2005

ture:

Docket No.: SCHERING 3.0-122 CIP (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Anil Saksena

Application No.: 10/052,386

: Group Art Unit: 1653

Filed: January 18, 2002

: Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE

PROTEASE INHIBITORS OF

HEPATITIS C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT IN CONNECTION WITH REQUEST FOR CONTINUED EXAMINATION

Dear Sir:

In connection with a Request for Continued Examination, Applicants submit the following amendments and remarks. Furthermore, an Information Disclosure Statement has been filed contemporaneously herewith.